Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

Recombinant analogue of the sea anemone Heteractis magnifica peptide was obtained, and the kinetic parameters of its interaction with mammalian α-amylases were determined. Magnificamide inhibits α-amylases significantly stronger than the medical drug acarbose (Precose TM or Glucobay TM ). Magnificam...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Doklady. Biochemistry and biophysics 2019-11, Vol.489 (1), p.385-387
Hauptverfasser:	Sintsova, O. V., Leychenko, E. V., Gladkikh, I. N., Kalinovskii, A. P., Monastyrnaya, M. M., Kozlovskaya, E. P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acarbose alpha-Amylases - antagonists & inhibitors Amino Acid Sequence Animals Biochemistry Biological and Medical Physics Biomedical and Life Sciences Biophysics Diabetes mellitus (non-insulin dependent) Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology Life Sciences Metabolic disorders Molecular Biology Peptides - chemistry Peptides - pharmacology Sea Anemones - chemistry α-Amylase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recombinant analogue of the sea anemone Heteractis magnifica peptide was obtained, and the kinetic parameters of its interaction with mammalian α-amylases were determined. Magnificamide inhibits α-amylases significantly stronger than the medical drug acarbose (Precose TM or Glucobay TM ). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.
ISSN:	1607-6729 1608-3091
DOI:	10.1134/S1607672919060097